Humalog (lispro) for type 2 diabetes

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1541-1550

  Esposito, Katherine ^a   Capuano, Annalisa ^a   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

ILPS; Insulin analogues; Lispro; Lispro mixtures; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; PROTAMINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PROCEDURES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN LISPRO; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867322035     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.728584     Document Type: Review

References (53)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21
2. Diabetes Data and Trends. Atlanta, GA: centers for Disease Control and Prevention. 2009. Available from: http://www.cdc.gov/diabetes/statistics/ incidence/fig1.htm [Last accessed 14 June 2012]
3. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and strokestatistics-2011 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2011; 123:e18-e209
4. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care 2012; 35(Suppl 1):S11-63
5. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898
6. Giugliano D, Ceriello A, Esposito K. HbA(1c) targets for type 2 diabetes: how many, ...how far!. Diabetes Res Clin Pract 2012;96:414-15
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
8. The AMD Annals 2009 Working Group. Longitudinal analysis of quality indicators of diabetes care in Italy (2004 - 2007). Associazione Medici Diabetologi, Rome. 2009. Available from: http://www.infodiabetes.it/files/2009- annali-AMD-eng.pdf [Last accessed 14 June 2012]
9. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010; 33:1759-65
10. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9
11. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994 - 2007. Arch Intern Med 2008; 168:2088-94
12. Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008;149:549-59
13. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180:385-97
14. Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-32
15. Giugliano D, Maiorino MI, Bellastella G, et al. Treatment regimens with insulin analogues and haemoglobin A1c target of < 7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2011;92:1-10
16. Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target < 7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012;14:228-33
17. Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012;379(9833):2262-9
18. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-9
19. Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010;12:916-22
20. Fogelfeld L, Dharmalingam M, Robling K, et al. Randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with type 2 diabetes. Diabet Med 2010;27:181-8
21. Arakaki RF, Blevins TC, Liljenquist DR, et al. Efficacy and safety of insulin lispro protamine suspension versus insulin glargine added to oral antihyperglycemic medications and exenatide in patients with type 2 diabetes [abstract]. Diabetologia 2010;53(Suppl 1):S-390
22. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999;22:1258-61
23. Herz M, Sun B, Milicevic Z, et al. Comparative efficacy of preprandial or postprandial humalog@ Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther 2002;24:73-86
24. Roach P, Arora V, Campaigne BN, et al. The India Mix25/Mix50 Study Group. Humalog Mix50TM before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 2003;5:311-16
25. Tigoviste CI, Strachinariu R, Farcasiu E, et al. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Rom J Intern Med 2003;41:152-62
26. Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract 2003;62:187-95
27. Malone JK, Kerr LF, Campaigne BN, Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44
28. Schernthaner G, Kopp H-P, Ristic S, et al. Metabolic control in patients with type 2 diabetes using humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004;36:188-93
29. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period,crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26(4):531-40
30. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22:374-81
31. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8:448-55
32. Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-52
33. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64
34. Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5
35. Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009; 32:1007-13
36. Milicevic Z, Hancu N, Car N, et al. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. Exp Clin Endocrinol Diabetes 2009;117:223-9
37. Jain SM, Mao X, Escalante-Pulido M, et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:967-75
38. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:1249-55
39. . Bastyr EJ; IIIStuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000;23:1236-41
40. Ross SA, Zinman B, Campos RV, Strack T; Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001;24:292-8
41. Forst T, Eriksson JW, Strotmann HJ, et al. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:97-103
42. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-84
43. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6
44. Gross JL, Nakano M, Colon-Vega G, et al. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: a randomized noninferiority trial. Diabetes Technol Ther 2009; 11(Suppl 2):S27-34
45. Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of insulin analogues in achieving the hemoglobin A1c target of < 7% in type 2 diabetes. Diabetes Care 2011;34:510-17
46. Koivisto V, Cleall S, Pontiroli AE, Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diab Obes Metab 2011;13:1149-57
47. Giugliano D, Maiorino M, Bellastella G, et al. Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. J Diabetes Complications 2011; 25:275-81
48. Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012;14:1-4
49. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010; 21:610-18
50. Cao W, Ning J, Yang X, Liu Z. Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis. Curr Mol Pharmacol 2011;4:154-66
51. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28
52. Esposito K, Giugliano D. Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opin Biol Ther 2012;12:209-21
53. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15(9):728-40.